Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000071.xml
Download PDF
Semin Neurol 2015; 35(06): 656-666
DOI: 10.1055/s-0035-1564682
DOI: 10.1055/s-0035-1564682
Fulminant Demyelinating Diseases of the Central Nervous System
Authors
Further Information
Publication History
Publication Date:
23 November 2015 (online)
Abstract
Fulminant demyelinating diseases of the central nervous system include acute disseminated encephalomyelitis, the related acute hemorrhagic leukoencephalitis, multiple sclerosis variants, neuromyelitis optica spectrum disorders, and idiopathic transverse myelitis. These syndromes are often managed with similar acute treatments including high-dose corticosteroids and plasmapheresis; however, long-term management varies. Although the prognosis of fulminant demyelinating disease was historically poor, outcomes today may be improved due to earlier diagnosis, rapid implementation of anti-inflammatory therapies such as high-dose corticosteroids and plasmapheresis, and improved supportive care.
-
References
- 1 Wallner-Blazek M, Rovira A, Fillipp M , et al. Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis. J Neurol 2013; 260 (8) 2016-2022
- 2 Lucchinetti CF, Gavrilova RH, Metz I , et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 2008; 131 (Pt 7) 1759-1775
- 3 Krupp LB , et al. International Pediatric Multiple Sclerosis Study Group. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013; 19 (10) 1261-1267
- 4 Menge T, Hemmer B, Nessler S , et al. Acute disseminated encephalomyelitis: an update. Arch Neurol 2005; 62 (11) 1673-1680
- 5 Leake JA, Albani S, Kao AS , et al. Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features. Pediatr Infect Dis J 2004; 23 (8) 756-764
- 6 Alper G, Heyman R, Wang L. Multiple sclerosis and acute disseminated encephalomyelitis diagnosed in children after long-term follow-up: comparison of presenting features. Dev Med Child Neurol 2009; 51 (6) 480-486
- 7 Young NP, Weinshenker BG, Lucchinetti CF. Acute disseminated encephalomyelitis: current understanding and controversies. Semin Neurol 2008; 28 (1) 84-94
- 8 Hynson JL, Kornberg AJ, Coleman LT, Shield L, Harvey AS, Kean MJ. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology 2001; 56 (10) 1308-1312
- 9 Pellegrino P, Radice S, Clementi E. Acute disseminated encephalomyelitis following influenza vaccine. Epidemiology 2015; 26 (1) e12-e13
- 10 Williams SE, Pahud BA, Vellozzi C , et al. Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination. Vaccine 2011; 29 (46) 8302-8308
- 11 Callen DJ, Shroff MM, Branson HM , et al. Role of MRI in the differentiation of ADEM from MS in children. Neurology 2009; 72 (11) 968-973
- 12 Hu W, Lucchinetti CF. The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol 2009; 31 (4) 439-453
- 13 Neuteboom RF, Boon M, Catsman Berrevoets CE , et al. Prognostic factors after a first attack of inflammatory CNS demyelination in children. Neurology 2008; 71 (13) 967-973
- 14 Mikaeloff Y, Caridade G, Husson B, Suissa S, Tardieu M ; Neuropediatric KIDSEP Study Group of the French Neuropediatric Society. Acute disseminated encephalomyelitis cohort study: prognostic factors for relapse. Eur J Paediatr Neurol 2007; 11 (2) 90-95
- 15 Kuni BJ, Banwell BL, Till C. Cognitive and behavioral outcomes in individuals with a history of acute disseminated encephalomyelitis (ADEM). Dev Neuropsychol 2012; 37 (8) 682-696
- 16 Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000; 123 (Pt 12) 2407-2422
- 17 Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology 2002; 59 (8) 1224-1231
- 18 Hart MN, Earle KM. Haemorrhagic and perivenous encephalitis: a clinical-pathological review of 38 cases. J Neurol Neurosurg Psychiatry 1975; 38 (6) 585-591
- 19 Ryan LJ, Bowman R, Zantek ND , et al. Use of therapeutic plasma exchange in the management of acute hemorrhagic leukoencephalitis: a case report and review of the literature. Transfusion 2007; 47 (6) 981-986
- 20 Robinson CA, Adiele RC, Tham M, Lucchinetti CF, Popescu BF. Early and widespread injury of astrocytes in the absence of demyelination in acute haemorrhagic leukoencephalitis. Acta Neuropathol Commun 2014; 2: 52
- 21 Wattamwar PR, Baheti NN, Kesavadas C, Nair M, Radhakrishnan A. Evolution and long term outcome in patients presenting with large demyelinating lesions as their first clinical event. J Neurol Sci 2010; 297 (1–2) 29-35
- 22 Haupts MR, Schimrigk SK, Brune N , et al. Fulminant tumefactive multiple sclerosis: therapeutic implications of histopathology. J Neurol 2008; 255 (8) 1272-1273
- 23 Kiriyama T, Kataoka H, Taoka T , et al. Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm. J Neuroimaging 2011; 21 (2) e69-e77
- 24 Balo J. Encephalitis periaxialis concentrica. Arch Neurol Psychiatry 1928; 19 (2) 242-264
- 25 Chaodong Wang, Zhang KN, Wu XM , et al. Balo's disease showing benign clinical course and co-existence with multiple sclerosis-like lesions in Chinese. Mult Scler 2008; 14 (3) 418-424
- 26 Kastrup O, Stude P, Limmroth V. Balo's concentric sclerosis. Evolution of active demyelination demonstrated by serial contrast-enhanced MRI. J Neurol 2002; 249 (7) 811-814
- 27 Karaarslan E, Altintas A, Senol U , et al. Baló's concentric sclerosis: clinical and radiologic features of five cases. AJNR Am J Neuroradiol 2001; 22 (7) 1362-1367
- 28 Seewann A, Enzinger C, Filippi M , et al; MAGNIMS network. MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain: a review of reported findings. J Neurol 2008; 255 (1) 1-10
- 29 Ng SH, Ko SF, Cheung YC, Wong HF, Wan YL. MRI features of Balo's concentric sclerosis. Br J Radiol 1999; 72 (856) 400-403
- 30 Kira J. Astrocytopathy in Balo's disease. Mult Scler 2011; 17 (7) 771-779
- 31 Masuda H, Mori M, Katayama K, Kikkawa Y, Kuwabara S. Anti-aquaporin-4 antibody-seronegative NMO spectrum disorder with Baló's concentric lesions. Intern Med 2013; 52 (13) 1517-1521
- 32 Markiewicz D, Adamczewska-Goncerzewicz Z, Dymecki J, Goncerzewicz A. A case of primary form of progressive multifocal leukoencephalopathy with concentric demyelination of Baló type. Neuropatol Pol 1977; 15 (4) 491-500
- 33 Chitnis T, Hollmann TJ. CADASIL mutation and Balo concentric sclerosis: a link between demyelination and ischemia?. Neurology 2012; 78 (3) 221-223
- 34 Ferreira D, Castro S, Nadais G, Dias Costa JM, Fonseca JM. Demyelinating lesions with features of Balo's concentric sclerosis in a patient with active hepatitis C and human herpesvirus 6 infection. Eur J Neurol 2011; 18 (1) e6-e7
- 35 Hickey WF. The pathology of multiple sclerosis: a historical perspective. J Neuroimmunol 1999; 98 (1) 37-44
- 36 Johnson MD, Lavin P, Whetsell Jr WO. Fulminant monophasic multiple sclerosis, Marburg's type. J Neurol Neurosurg Psychiatry 1990; 53 (10) 918-921
- 37 Walid MS, Sanoufa M. The diagnosis of Marburg disease is course-dependent. Ger Med Sci 2010; 8: Doc06
- 38 Cañellas AR, Gols AR, Izquierdo JR, Subirana MT, Gairin XM. Idiopathic inflammatory-demyelinating diseases of the central nervous system. Neuroradiology 2007; 49 (5) 393-409
- 39 Capello E, Mancardi GL. Marburg type and Balò's concentric sclerosis: rare and acute variants of multiple sclerosis. Neurol Sci 2004; 25 (Suppl. 04) S361-S363
- 40 Wingerchuk DM, Banwell B, Bennett JL , et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85 (2) 177-189
- 41 Popescu BF, Lennon VA, Parisi JE , et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 2011; 76 (14) 1229-1237
- 42 Kremer S, Renard F, Achard S , et al; Guthy-Jackson Charitable Foundation (GJCF) Neuromyelitis Optica (NMO) International Clinical Consortium and Biorepository. Use of advanced magnetic resonance imaging techniques in neuromyelitis optica spectrum disorder. JAMA Neurol 2015; 72 (7) 815-822
- 43 Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 1993; 34 (2) 162-168
- 44 Lennon VA, Wingerchuk DM, Kryzer TJ , et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364 (9451) 2106-2112
- 45 Nicchia GP, Nico B, Camassa LM , et al. The role of aquaporin-4 in the blood-brain barrier development and integrity: studies in animal and cell culture models. Neuroscience 2004; 129 (4) 935-945
- 46 Misu T, Fujihara K, Nakamura M , et al. Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report. Tohoku J Exp Med 2006; 209 (3) 269-275
- 47 Sinclair C, Kirk J, Herron B, Fitzgerald U, McQuaid S. Absence of aquaporin-4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal-appearing white matter. Acta Neuropathol 2007; 113 (2) 187-194
- 48 Malik R, Lewis A, Cree BA , et al. Transient hyperckemia in the setting of neuromyelitis optica (NMO). Muscle Nerve 2014; 50 (5) 859-862
- 49 Bennett JL, Lam C, Kalluri SR , et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009; 66 (5) 617-629
- 50 Bradl M, Misu T, Takahashi T , et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009; 66 (5) 630-643
- 51 Jarius S, Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol 2013; 23 (6) 661-683
- 52 Cree BA, Goodin DS, Hauser SL. Neuromyelitis optica. Semin Neurol 2002; 22 (2) 105-122
- 53 Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002; 58 (1) 143-146
- 54 Magaña SM, Keegan BM, Weinshenker BG , et al. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol 2011; 68 (7) 870-878
- 55 Sato D, Callegaro D, Lana-Peixoto MA, Fujihara K ; Brazilian Committee for Treatment and Research in Multiple Sclerosis. Treatment of neuromyelitis optica: an evidence based review. Arq Neuropsiquiatr 2012; 70 (1) 59-66
- 56 Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53 (5) 1107-1114
- 57 Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003; 60 (5) 848-853
- 58 Torres J, Pruitt A, Balcer L, Galetta S, Markowitz C, Dahodwala N. Analysis of the treatment of neuromyelitis optica. J Neurol Sci 2015; 351 (1–2) 31-35
- 59 Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002; 59 (4) 499-505
- 60 Tanenbaum LN. Clinical applications of diffusion imaging in the spine. Magn Reson Imaging Clin N Am 2013; 21 (2) 299-320
- 61 Wullschleger A, Kapina V, Molnarfi N , et al. Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases. PLoS ONE 2013; 8 (8) e72399
- 62 de Seze J, Lanctin C, Lebrun C , et al. Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology 2005; 65 (12) 1950-1953
- 63 Bruna J, Martínez-Yélamos S, Martínez-Yélamos A, Rubio F, Arbizu T. Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases. Mult Scler 2006; 12 (2) 169-173
- 64 Kahloon AA, Arif H, Baig SM, Khawaja MR. Characteristics of acute transverse myelitis at Aga Khan University Hospital, Karachi. J Pak Med Assoc 2007; 57 (4) 215-218
- 65 Pidcock FS, Krishnan C, Crawford TO, Salorio CF, Trovato M, Kerr DA. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology 2007; 68 (18) 1474-1480
- 66 Kalita J, Misra UK. Is methyl prednisolone useful in acute transverse myelitis?. Spinal Cord 2001; 39 (9) 471-476
- 67 Defresne P, Hollenberg H, Husson B , et al. Acute transverse myelitis in children: clinical course and prognostic factors. J Child Neurol 2003; 18 (6) 401-406
- 68 Lahat E, Pillar G, Ravid S, Barzilai A, Etzioni A, Shahar E. Rapid recovery from transverse myelopathy in children treated with methylprednisolone. Pediatr Neurol 1998; 19 (4) 279-282
- 69 Sébire G, Hollenberg H, Meyer L, Huault G, Landrieu P, Tardieu M. High dose methylprednisolone in severe acute transverse myelopathy. Arch Dis Child 1997; 76 (2) 167-168
- 70 Greenberg BM, Thomas KP, Krishnan C, Kaplin AI, Calabresi PA, Kerr DA. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology 2007; 68 (19) 1614-1617
- 71 Chan KH, Tsang KL, Fong GC, Ho SL, Cheung RT, Mak W. Idiopathic inflammatory demyelinating disorders after acute transverse myelitis. Eur J Neurol 2006; 13 (8) 862-868
- 72 Beck RW, Cleary PA, Anderson Jr MM , et al; The Optic Neuritis Study Group. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992; 326 (9) 581-588
- 73 Le Page E, Veillard D, Laplaud DA , et al; COPOUSEP investigators; West Network for Excellence in Neuroscience. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet 2015; 6736 (15) 611-637
- 74 Weinshenker BG, O'Brien PC, Petterson TM , et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46 (6) 878-886
- 75 Visser LH, Beekman R, Tijssen CC , et al. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 2004; 10 (1) 89-91
- 76 Ravaglia S, Piccolo G, Ceroni M , et al. Severe steroid-resistant post-infectious encephalomyelitis: general features and effects of IVIg. J Neurol 2007; 254 (11) 1518-1523
- 77 Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64 (7) 1270-1272
- 78 Siffrin V, Müller-Forell W, von Pein H, Zipp F. How to treat tumefactive demyelinating disease?. Mult Scler 2014; 20 (5) 631-633
- 79 Sempere AP, Feliu-Rey E, Sanchez-Perez R, Nieto-Navarro J. Neurological picture. Rituximab for tumefactive demyelination refractory to corticosteroids and plasma exchange. J Neurol Neurosurg Psychiatry 2013; 84 (12) 1338-1339
- 80 Fan X, Mahta A, De Jager PL, Kesari S. Rituximab for tumefactive inflammatory demyelination: a case report. Clin Neurol Neurosurg 2012; 114 (10) 1326-1328
- 81 Nozaki K, Abou-Fayssal N. High dose cyclophosphamide treatment in Marburg variant multiple sclerosis A case report. J Neurol Sci 2010; 296 (1–2) 121-123
- 82 Hardy TA, Chataway J. Tumefactive demyelination: an approach to diagnosis and management. J Neurol Neurosurg Psychiatry 2013; 84 (9) 1047-1053
- 83 Brown JW, Coles AJ, Jones JL. First use of alemtuzumab in Balo's concentric sclerosis: a case report. Mult Scler 2013; 19 (12) 1673-1675
- 84 Hauser SL, Waubant E, Arnold DL , et al; HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358 (7) 676-688
- 85 Kappos L, Li D, Calabresi PA , et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011; 378 (9805) 1779-1787
- 86 Sorensen PS, Lisby S, Grove R , et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology 2014; 82 (7) 573-581
- 87 Latimer-Cheung AE, Pilutti LA, Hicks AL , et al. Effects of exercise training on fitness, mobility, fatigue, and health-related quality of life among adults with multiple sclerosis: a systematic review to inform guideline development. Arch Phys Med Rehabil 2013; 94 (9) 1800-1828.e3